J&J Sues Sun to Block Invega Sustenna Copies After Patent Win

Johnson & Johnson’s Janssen units filed lawsuits in two federal courts alleging Sun Pharmaceutical Industries Ltd.'s proposed copies of the schizophrenia drug Invega Sustenna infringe a patent the Federal Circuit upheld earlier this week.

The generics proposed by the Indian drugmaker and its US affiliate infringe US Patent No. 9,439,906, which covers a dosing regimen essential to Invega Sustenna’s safe and effective use, according to complaints filed Thursday in the US District Court for the District of Delaware and July 9 in the District of New Jersey. The patent is the only one listed for Invega Sustenna in the ...